iPSC-Derived Islet Cell Therapy
Type 1 and Type 2 Diabetes
Clinical Trials (phase unspecified)Active
Key Facts
Indication
Type 1 and Type 2 Diabetes
Phase
Clinical Trials (phase unspecified)
Status
Active
About Regenerative Medical Solutions
Regenerative Medical Solutions (RMS) is a clinical-stage biotech company pioneering an iPSC-derived islet cell therapy as a potential functional cure for diabetes. Founded in 2012 based on decades of academic research from Dr. Jon Odorico's lab at the University of Wisconsin, the company is developing a scalable cell product designed to avoid the need for heavy immunosuppression or implantable devices. RMS is actively seeking investment and strategic partnerships with pharmaceutical and biotech companies to advance its therapy through clinical trials and to the market.
View full company profileTherapeutic Areas
Other Type 1 and Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Clinical Trials | Diablo Clinical Research | Phase 1-3 |
| Glucose-Responsive Insulin | Sensulin | Preclinical |